MIRROR 2017.
Trial name or title | Efficacy of the Telescopic Mirror Implant for Age‐related Macular Degeneration: The MIRROR Trial |
Methods | Parallel‐group, randomized clinical trial |
Participants | End‐stage age‐related macular degeneration |
Interventions | OriLens device vs. optimized low vision training with the opportunity to try external telescopes |
Outcomes | Primary outcome: best‐corrected distance visual acuity, measured using number of letters improvement on ETDRS chart at 12 months Secondary outcomes: best‐corrected distance visual acuity at one, three and six months; best‐corrected near visual acuity, reading speed and contrast sensitivity, measured by MNRead chart and MARS chart at 12 months; vision‐specific quality of life, measured using the IVI at six and 12 months; health‐related quality of life status, measured using the EQ‐5D‐5L questionnaire at six and 12 months; health service use and associated costs, measured by a Health Service Use Questionnaire at six and 12 months |
Starting date | 2015 |
Contact information | Dr Catherine Adams The Royal Hospitals Belfast, UK |
Notes | Intention to publish date: 28 February 2020 |